US 7,566,450 B2
	Humanized anti-CCR2 antibodies and methods of use therefor
Gregory J. LaRosa, Newton, Mass. (US); Christopher J. Horvath, Taunton, Mass. (US); Walter Newman, Boston, Mass. (US); S. Tarran Jones, Hertfordshire (United Kingdom); Siobhan H. O'Brien, London (United Kingdom); and Theresa O'Keefe, Waltham, Mass. (US)
Assigned to Millennium Pharmaceuticals, Inc., Cambridge, Mass. (US)
Filed on Oct. 26, 2007, as Appl. No. 11/924,794.
Application 11/924794 is a continuation of application No. 10/766773, filed on Jan. 27, 2004, granted, now 7,473,421.
Application 10/766773 is a continuation of application No. 09/497625, filed on Feb. 03, 2000, granted, now 6,727,349, filed on Apr. 27, 2004.
Application 09/497625 is a continuation in part of application No. 09/359193, filed on Jul. 22, 1999, granted, now 6,352,832, filed on Mar. 05, 2002.
Application 09/359193 is a continuation in part of application No. 09/121781, filed on Jul. 23, 1998, granted, now 6,312,689, filed on Nov. 06, 2001.
Prior Publication US 2008/0241136 A1, Oct. 02, 2008
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01)

U.S. Cl. 424—139.1  [424/142.1; 424/143.1]

18 Claims

1. A method of treating scleroderma in a patient, comprising administering to a patient having scleroderma a composition comprising an effective amount of a humanized antibody or antigen-binding fragment thereof having binding specificity for CC-chemokine receptor 2 (CCR2), said antibody or antigen-binding fragment thereof inhibits binding of a chemokine to CCR2 and inhibits one or more function associated with binding of the chemokine to the CCR2.